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Recently, the number of reports on isolation of ciprofloxacin resistant Campylobacter
jejuni has increased worldwide. The aim of this study was to determine the prevalence
of resistance to ciprofloxacin and its genetic determinants among C. jejuni isolated from
humans (n = 100), poultry products (n = 96) and wild birds (n = 96) in Lithuania. 91.4%
of the C. jejuni isolates were phenotypically resistant to ciprofloxacin. DNA sequence
analyses of the gyrA gene from 292 isolates revealed that a change in amino acid
sequence, Thr86Ile, was the main substition conferring resistance to ciprofloxacin. This
change was significantly associated with isolates from poultry products (P < 0.05) and
humans (P < 0.05). A total of 26.7% of C. jejuni isolates from human (n = 47), poultry
products (n = 30) and wild bird (n = 1), had a mutation from Ser at position 22, and six
had an additional mutation from Ala at position 39. Eight isolates from poultry and two
isolates from human, corresponding to 67.0% of isolates with MICs≥128µg/ml, showed
missense mutations Thr86Ile (ACA→ATA) and Ser22Gly (AGT→GGT) together, whereas
isolates without these mutations showed lower MIC values (from 4 to 64µg/ml). Two
hundred forty-five C. jejuni isolates showed one or more silent mutations, and 32.4%
of examined isolates possessed six silent mutations. In addition to the ciprofloxacin
resistant isolates harboring only Thr86Ile point mutation (110 isolates), the current study
identified resistant isolates (n = 101) harboring additional point mutations (Ser22Gly,
Ala39Ser, Arg48Lys, Thr85Ala Ala122Ser, Glu136Asp, Vall49Ile), and strains (n = 57)
having only Glu136Asp point mutation. The study highlight the potential public health
problemwith elevated ciprofloxacin resistance inCampylobacters from poultry meat, wild
birds and humans, and the need for extensive surveillance enabling to follow changes of
antimicrobial resistance development in this species.
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INTRODUCTION
Campylobacter jejuni is a leading foodborne pathogen in many countries (Engberg et al., 2001).
It colonizes the gastrointestinal tracts of a wide range of wild, domestic, and livestock animals,
and foods of animal origin are a significant source of campylobacteriosis in humans (Colles
et al., 2008; Silva et al., 2011). Transmission of C. jejuni to humans most often occurs via to
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consumption of contaminated food, especially chicken
meat, or by direct contact with feces (Miller et al., 2010).
Although most infections are mild and self-limiting and do
not require antimicrobial therapy, treatment is indicated
in immunocompromised patients, or if the infection is
extraintestinal (Goodman et al., 1984). Fluoroquinolones,
such as ciprofloxacin, are the antimicrobial agents of choice
for treatment of campylobacteriosis (Guerrant et al., 2001;
Blaser and Engberg, 2008). Other antimicrobials, however,
such as erythromycin, azithromycin and gentamicin may be
viable alternatives (Wieczorek and Osek, 2013; Wimalarathna
et al., 2013). Moreover, fluoroquinolones have been used as
first-line antibiotics against bacterial gastroenteritis in the
absence of microbiological diagnosis (Wieczorek, 2011). The
quinolones target two large, bacterial enzymes, DNA gyrase
and topoisomerase IV, and binding to these enzymes inhibit
the synthesis of bacterial DNA, causing cell death. Resistance
to fluoroquinolones is mainly due to amino acids substitutions
in the quinolone resistance-determining region (QRDR) of the
topoisomerase (Wieczorek and Osek, 2013). Due to common
use of flouroquinolones in livestock in some countries, and
for treatment of campylobacteriosis in humans, resistance to
this antimicrobial group has emerged worldwide in C. jejuni
and has become a public health issue (Abay et al., 2014; Sahin
et al., 2015). Resistance to quinolones in Campylobacter is
usually mediated by a single point mutation in the quinolone
resistance-determining region (QRDR) of the gyrA gene at codon
86 (ACA→ATA), leading to isoleucine substitution for threonine
(Wang et al., 1993; Ruiz et al., 1998; Zirnstein et al., 1999). This
alteration is most often associated with high MIC values for
fluoroquinolones (Wang et al., 1993). Other substitutions in the
QRDR are also known and described, but these changes are less
common (Wang et al., 1993; Hakanen et al., 2003).
The prevalence of resistance to ciprofloxacin in
Campylobacter species vary considerably between countries,
with high prevalence reported in Poland (Wieczorek and Osek,
2013), Italy (Di Giannatale et al., 2014), Switzerland (Kittl
et al., 2013) and some other EU countries (EFSA, 2014a,b).
The rapid emergence of antimicrobial resistance is a cause for
global concern (Engberg et al., 2001; Hein et al., 2003). To
our knowledge, there are no published data on the genetic
background for flouroquinolone resistance in C. jejuni isolated
from different sources in Lithuania. Therefore, the aim of
this study was to determine the prevalence of resistance to
ciprofloxacin among C. jejuni isolated from humans, poultry
products and wild birds in Lithuania, and to assess the gyrA
mutations responsible for the resistance among the C. jejuni
isolates.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
A total of 292 C. jejuni isolates from infected children (n = 100),
raw (n = 77), and marinated (n = 19) broiler products and wild
birds: pigeons (n = 39) and crows (n = 57) were selected. Food
and wild bird isolates were from the Campylobacter collection at
the Department of Food Safety andQuality, Veterinary Academy,
Lithuanian University of Health Sciences. The human C. jejuni
isolates were received from the Microbiological laboratory of
Kaunas Clinical Hospital and were isolated in the period from
2011 to 2012. Identification of Campylobacter isolates was
performed withmultiplex PCR as described byWang et al. (2002)
with the minor modifications described previously by Ramonaite
et al. (2015).
Campylobacter isolates were stored as frozen stocks at −80◦C
in in brain heart infusion broth (BHI) (Oxoid Ltd., Basingstoke,
UK) with 30% glycerol (Stanlab, Poland). They were recovered
from frozen stocks on Blood agar base No. 2 (Oxoid, Basingstoke,
Hampshire, England) supplemented with 5% defibrinated
horse blood (E&O Laboratories, Burnhouse, Bonnybridge,
Scotland) and incubated under microaerophilic conditions (5%
oxygen, 10% carbon dioxide and 85% nitrogen) at 37◦C
for 48 h.
Antimicrobial Resistance Testing
Minimum inhibitory concentrations (MIC) were determined
according to the recommendations of the Clinical and Laboratory
Standarts Institute (CLSI) (CLSI, 2006). Antimicrobial
susceptibility was evaluated using the quality control strain
C. jejuni ATCC 33560. Briefly, suspension of C. jejuni isolates
adjusted to an OD600 = 0.1 were prepared in phosphate
buffered saline and inoculated onto Mueller-Hinton agar
(LiofilChem, Milan Italy) supplemented with 5% lysed sheep
blood (E&O Laboratories, Burnhouse, Bonnybridge, Scotland)
and ciprofloxacin (Sigma-Aldrich, Saint-Louis, USA) in
concentrations ranging from 0.25 to 256µg/ml and incubated
under microaerophilic conditions at 42◦C for 24 h. The MIC
interpretive criterion for resistance to ciprofloxacin was
≥4µg/ml.
DNA Extraction
Bacterial isolates were grown at 37◦C on blood agar plates for
48 h under microaerophilic conditions. After sufficient growth
was obtained, one 1 µl loopful of bacteria was suspended in
Eppendorf tubes containing 200 µl of PrepMan Ultra Sample
Preparation Reagent (PrepManTM Ultra, Applied Biosystems,
USA). DNA extraction was carried out following the instructions
of the supplier including heating of bacterial suspension at 100◦C
for 10min., centrifugation at 16,000 g for 3min. and transferring
the supernatants into new tubes before storage in the freezer at
−20◦C until use.
PCR Detection of Antibiotic Resistance
Determinants
The QRDR of the gyrA gene of the C. jejuni isolates was amplified
by MAMA PCR as described by Zirstein (Zirnstein et al., 1999)
using GzgyrA5 and GzgyrA6 primers for amplification of a 673
bp product (Table 1). Forward primer CampyMAMAgyrA1 and
a reverse primer CampyMAMAgyrA5 (Table 1) were used to
generate a 256 bp PCR product that was a positive indication of
the presence of the Thr-86-Ile (ACA→ATA) mutation in the C.
jejuni gyrA gene. Primer GZgyrA4, a conserved reverse primer,
was used in conjugation with primer CampyMAMAgyrA1 to
produce a positive PCR control product of 368 bp with any
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TABLE 1 | Primers used for PCR in this study.
MAMA PCR
Primer Sequence (5′→3′) Direction References
GZgyrA4 cagtataacgcatcgcagcg Reverse Zirnstein
et al., 1999GZgyrA5 atttttagcaaagattctgat Forward
GZgyrA6 ccataaattattccacctgt Reverse
GZgyrA7 ttattataggtcgtgctttg Nested forward
GZgyrA8 tagaaggtaaaacatcaggtt Nested reverse
CampyMAMAgyrA1 tttttagcaaagattctgat Forward
CampyMAMAgyrA5 caaagcatcataaactgcaa Reverse
gyrA gctgatgcaaaagkttaatatgc Forward Ragimbeau
et al., 2014gyrA tttgtcgccatacctacagc Reverse
C. jejuni gyrA gene. PCR cycling conditions were as follow:
3min initial denaturation at 94◦C, followed by 30 cycles of
denaturation at 94◦C for 1min, annealing at 54◦C for 1min
and extension at 72◦C for 1min, with a final step at 72◦C
for 5min.
DNA Sequencing and Sequence Analysis
Nested primers GZgyrA7 and GZgyrA8 (Table 1), which are
internal to the 673 bp gyrA PCR products produced above,
were used for sequencing. The partial gene sequence of
gyrA, generated by use of CampyMAMAgyrA1 and a reverse
primer CampyMAMAgyrA5 targeting the quinolone resistance
determining region (QRDR), was sequenced with the forward
and reverse primers described by Ragimbeau et al. (Table 1). The
amplification protocol consisted of 95◦C for 10min, followed by
35 cycles of 95◦C 30 s, 55◦C 30 s, and 72◦C 50 s. The reaction was
completed by a final extension of 5min at 72◦C.
The PCR amplicons were purified using the GeneJet
PCR purification system (Thermo Scientific, EU). Sequencing
reactions were carried out using the BigDye Terminator 3.1
cycle Sequencing Kit (Applied Biosystems, USA) according to
instructions from the manufacturer. Duplicate forward and
reverse sequencing reactions were run with forward and reverse
primers, respectively, for each sample. The samples were
analyzed with a 3500 Genetic Analyzer (Applied Biosystems).
The BioNumerics program 7.0 (Applied Maths NV, USA,
EU) was used to evaluate the specific genomic mutations
associated with resistance to ciprofloxacin, including comparison
to the reference C. jejuni strain ATCC 700819 genome (NCTC
11168).
Statistical Analysis
The statistical package SPSS (Statistics 20, IBM) was used.
Comparison of association between phenotypic resistance and
resistance genes in C. jejuni from humans, poultry products and
wild birds isolates and distributions of resistant isolates were
evaluated using the Chi-square test and Fisher’s exact test. A




Among the 292 isolates tested, 267 (91.4%) were phenotypically
resistant to ciprofloxacin (Table 2). In particular, all C. jejuni
isolates from poultry products were resistant to ciprofloxacin
with MIC ranging from 4µg/ml up to 256µg/ml.
PCR Typing of Resistant Isolates
Phenotypic resistance to ciprofloxacin matched genotypic
resistance of all isolates from broiler products and the vast
majority (93%) of isolates from humans. Out of the 267
ciprofloxacin-resistant isolates, the majority (76.4%; n = 204)
were positive for the Thr86Ile substitution of the gyrA gene
as demonstrated by PCR. The Thr86Ile substitution was not
detected in 62 wild bird isolates, which showed phenotypic
resistance to ciprofloxacin.
Amino Acid Sequences of the gyrA Gene in
Ciprofloxacin Resistant C. jejuni
We identified eight different missense amino acid substitutions
in the gyrA gene of the ciprofloxacin resistant C. jejuni isolates
(Table S1 in Supplementary Materials). One hundred and
ten C. jejuni isolates harbored a single Thr86Ile substitution
in gyrA without any other amino acid changes in this
region. One of the other substitutions was Ser22Gly, which is
known to confer fluoroquinolones resistance, often along with
the Thr86Ile substitution (Jesse et al., 2006). The combined
Thr86Ile (ACA→ATA) and Ser22Gly (AGT→GGT) changes
were detected in 10 out of the 15 ciprofloxacin-resistant C. jejuni
isolates with MICs ≥128µg/ml (67.0%). Seven isolates carried
the Ala39Ser substitution, and these isolates also had the Thr86Ile
amino acid change. Six isolates carried the Ser22Gly, Ala39Ser
and the Thr86Ile changes in combination, whereas only one
isolate carried four substitutions: Ser22Gly, Arg48Lys, Thr86Ile,
and Glu136Asp. Interestingly, four ciprofloxacin resistant C.
jejuni isolates had no point mutations in QRDR. Seventy-four
ciprofloxacin resistant C. jejuni isolates had a Glu136 point
mutation. This mutation was significantly more common in
isolates from wild birds (P < 0.05) than in isolates from poultry
product and humans. Table S1 in Supplementary Materials lists
the observed combinations of mutations in the gyrA QRDR.
The study revealed at least one silent mutation in 245 C. jejuni
isolates (Table 3), and 6 C. jejuni isolates harbored more than
six silent mutations. Details on the observed silent mutations
in relation to clonal lines can be seen from Table S1 in the
Supplementary Material.
Association between MLST Genotypes and
Phenotypic Antimicrobial Resistance
MLST types of the isolates investigated were published by
Ramonaite et al. (2015, 2017). In the current investigation, we
related QRDR sequence types to MLST type. The gyrA gene
point-mutations A64G, G118T and C257T were observed in four
isolates with ST-257 (CC257), in one isolate with ST-51 (CC443)
and one isolate with ST-6413 (CC353). In total 40 isolates having
the Thr-86-Ile substitution were assigned to CC353 and 31 of
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Poultry products 0.5–256 4–256 ≥4 96 (100)
Humans 0.5–256 1–128 ≥4 88 (88.0)
Wild birds 0.5–256 2–64 ≥4 83 (86.4)
TABLE 3 | Silent mutations in the gyrA QRDR of C. jejuni isolates and associated
ranges of MICs of ciprofloxacin.
Number
of strains
MIC (µg/ml) Nucleotide change Amino acid position
5 4–256 AAA→AAG Lys21→Lys
95 2–256 TAT→TAC Tyr24→tyr
3 4 TCT→TCC Ser28→Ser
1 16 GAC→GAT Asp39→Asp
2 2–32 GAG→GAA Glu59→Glu
2 4–8 GAA→GAG Glu63→Glu
1 2 CAG→CAA Gln69→Gln
7 2–128 GGT→GCC Gly78→Gly
141 2–256 CAC→CAT His81→His
1 16 AAG→AAA Lys97→Lys
3 2–32 GGC→GGT Gly110→Gly
2 4–8 GTG→GTC Val117→Val
3 4 ATA→ATC Ile118→Ile
216 2–256 AGT→AGC Ser119→Ser
150 2–128 GCC→GCT Ala120→Ala
1 16 AGC→AGT Ser137→Ser
2 4–8 AGC→AGT Ser145→Ser
1 8 TTC→TTT Phe149→Phe
6 4–256 TAT→TAC Tyr152→Tyr
181 2–256 AGC→AGT Ser157→Ser
127 2–256 GTT→GTC Val161→Val
33 isolates belonging to CC21. More than half of the isolates
(57.7%) belonging to an undefined clonal complex is isolated
from wild birds and had the Glu136Asp novel mutation (Table
S1 in Supplementary Materials).
DISCUSSION
Ciprofloxacin resistant Campylobacter isolates were observed
already from the late 1980s, indicating animals as themain source
of resistant bacteria. Currently, flouroquinolone resistance in
C. jejuni is emerging globally and is considered a problem of
public health importance (Wardak et al., 2007; Luangtongkum
et al., 2009; Wieczorek, 2011). In this study, C. jejuni isolates
originating from humans, poultry products and wild birds in
Lithuania were examined for resistance to ciprofloxacin.
A high prevalence of C. jejuni resistance to ciprofloxacin was
observed irrespective of the source of isolation (91.4%). This is
much higher resistance prevalence than has been reported in
other parts of the Baltic region. For example, Estonia reported
only 16.7% prevalence of this resistance (Mäesaar et al., 2016).
On the other hand, it is very similar to what has previously
been reported from isolates obtained from broiler meat in Latvia
and Lithuania (87.5 and 84.8%, respectively) (Mäesaar et al.,
2016). The Baltic region is not exceptional, as elevated levels
of ciprofloxacin resistance in C. jejuni have also been reported
from Poland (Wieczorek and Osek, 2013), Italy (Di Giannatale
et al., 2014), Switzerland (Kittl et al., 2013) and some other EU
countries (EFSA, 2014a,b). However, it should bementioned, that
prevalence of resistance can change dramatically over time.
Resistance to fluoroquinolones in Campylobacter is mainly
due to amino acids substitutions in the quinolone resistance-
determining region (QRDR) of gyrA (Wieczorek and Osek,
2013). The most frequently observed mutation is the C257T
mutation in the gyrA gene, which leads to the Thr86Ile
substitution in the gyrase, and confers high-level resistance to this
class of antimicrobials (Wang et al., 1993; Payot et al., 2006). In
confirmation of this and other studies (Kinana et al., 2006; Tang
et al., 2017), the Thr86Ile substitution was the most frequently
observed amino acid change in the current study. Previous
studies (Sonnevend et al., 2006; Boonmar et al., 2007; Wieczorek,
2011; Duarte et al., 2014) have reported that all ciprofloxacin
resistant C. jejuni carried the Thr86Ile amino acid substitution
in the QRDR of gyrA. However, while our study showed this
mutation in 100% of the broiler products isolates and 98.9%
of the human isolates, only 25.3% of the ciprofloxacin-resistant
wild bird isolates carried the corresponding mutation. Other
mechanisms of resistance, including decreased outer membrane
permeability and eﬄux systems, have been described (Charvalos
et al., 1996), and these may contribute to the phenotypic
resistance observed in the strains, where no amino acid changes
in gyrA were observed.
The Ser22Gly substitution alone may not confer ciprofloxacin
resistance, since it has been identified in susceptible strains
(Jesse et al., 2006; Tang et al., 2017). However, the double
substitution, Thr86Ile/Ser22Gly, is known to confer high-level
ciprofloxacin resistance in Campylobacter (Oishi et al., 2015). We
also identified the mutation leading to Ser22Gly substitution in
combination with the mutation leading to Thr86Ile substitution,
and the presence of bothmutations was associated with highMIC
values. Interestingly, one of the isolates with this combination
carried an additional double novel mutation, from Arg at
position 48 and from Glu at position 136. More research is
needed to clarified whether these novel mutations contribute to
phenotypic ciprofloxacin resistance in C. jejuni.
Silent mutation are often described in ciprofloxacin resistant
and sensitive strains and a high number of combinations
of transitions and mutations may exist (Frasao et al., 2015).
We confirmed this observation, and some of the most
frequently observed silent mutations at His-81→His, Ala-
119→Ala, and Ser-120→Ser corresponds to mutations described
in Campylobacter isolated in Finland and Brazil (Hakanen et al.,
2002; Frasao et al., 2015). Other transitions without amino acid
changes were frequently found in the QRDR, generating many
different gyrA alleles, TCT→TCC at the codon 84 described
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by Carattoli et al. (2002) and Gly-110→Gly (GGC→GGT)
described by Beckmann et al. (2004). However, we did not
observe silent mutation at Ser-75→Ser (GCT→GAT) and Ser-
79→Ser (CGT→AGT), as described by Frasao et al. (2015).
CONCLUSIONS
In conclusion, the phenotypic and genotypic antimicrobial
resistance of C. jejuni from human, poultry products and wild
birds to ciprofloxacin have been investigated and reported for the
first time in Lithuania. Our study demonstrated a high prevalence
of ciprofloxacin resistance in the isolates. The data presented here
confirmed previous findings that mutations in the gyrA gene at
position 257 aremainly responsible for ciprofloxacin resistance of
C. jejuni strains from poultry products and humans. In addition,
our results indicated that Glu136Asp mutation is associated
with high-level ciprofloxacin resistance among wild bird
isolates.
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